Literature DB >> 15652674

Interactions of proteoliposomes from serogroup B Neisseria meningitidis with bone marrow-derived dendritic cells and macrophages: adjuvant effects and antigen delivery.

Tamara Rodríguez1, Oliver Pérez, Nathalie Ménager, Sanja Ugrinovic, Gustavo Bracho, Pietro Mastroeni.   

Abstract

Exposure to proteoliposomes from serogroup B Neisseria meningitidis (PL) induced up-regulation of MHC-II, MHC-I, CD40, CD80 and CD86 expression on the surface of murine bone marrow-derived dendritic cells (DC). CD40, CD80 and CD86 were up-regulated on bone marrow-derived macrophages (MPhi) upon stimulation with PL. Both DC and MPhi released TNFalpha, but only DC produced IL12(p70) in response to PL. A small increase in the expression of MHC-II, CD40 and CD86, as well as production of IL12(p70), was observed on the cell surface of DC, but not MPhi from LPS-non-responder C3H/HeJ after exposure to PL. DC, but not MPhi, incubated with PL containing ovalbumin (PL-OVA) presented OVA-specific peptides to CD4+ and CD8+ OVA-specific T-cell hybridomas. These data clearly indicate that PL exert an immunomodulatory effect on DC and MPhi, with some contribution of non-LPS components besides the main role of LPS. The work also shows the potential of PL as a general system to deliver antigens to DC for presentation to CD4+ and CD8+ T-cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15652674     DOI: 10.1016/j.vaccine.2004.07.049

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant.

Authors:  C Venier; M D Guthmann; L E Fernández; L Fainboim
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

2.  Combined meningococcal serogroup A and W135 outer-membrane vesicles activate cell-mediated immunity and long-term memory responses against non-covalent capsular polysaccharide A.

Authors:  Belkis Romeu; Miriam Lastre; Luis García; Bárbara Cedré; Aleida Mandariote; Mildrey Fariñas; Reynaldo Oliva; Einar Rosenqvist; Oliver Pérez
Journal:  Immunol Res       Date:  2014-01       Impact factor: 2.829

Review 3.  Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations.

Authors:  O Pérez; A Batista-Duharte; E González; C Zayas; J Balboa; M Cuello; O Cabrera; M Lastre; V E J C Schijns
Journal:  Braz J Med Biol Res       Date:  2012-04-26       Impact factor: 2.590

4.  LOS oligosaccharide modification enhances dendritic cell responses to meningococcal native outer membrane vesicles expressing a non-toxic lipid A.

Authors:  Hannah E Jones; Alastair Copland; Hendrik Jan Hamstra; Jonathan Cohen; Jeremy Brown; Nigel Klein; Peter van der Ley; Garth Dixon
Journal:  Cell Microbiol       Date:  2013-11-06       Impact factor: 3.715

5.  Development of a novel S. Typhi and Paratyphi A outer membrane vesicles based bivalent vaccine against enteric fever.

Authors:  Debaki R Howlader; Hemanta Koley; Ritam Sinha; Suhrid Maiti; Ushasi Bhaumik; Priyadarshini Mukherjee; Shanta Dutta
Journal:  PLoS One       Date:  2018-09-14       Impact factor: 3.240

6.  Assessing the immunogenicity and toxicity of the AFPL1-conjugate nicotine vaccine using heterologous and homologous vaccination routes.

Authors:  Nya L Fraleigh; Reynaldo Oliva; Jordan D Lewicky; Alexandrine L Martel; Reinaldo Acevedo; García-Rivera Dagmar; Hoang-Thanh Le
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

7.  A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles.

Authors:  Darielys Santana-Mederos; Rocmira Perez-Nicado; Yanet Climent; Laura Rodriguez; Belinda Sanchez Ramirez; Sonia Perez-Rodriguez; Meybi Rodriguez; Claudia Labrada; Tays Hernandez; Marianniz Diaz; Ivette Orosa; Ubel Ramirez; Reynaldo Oliva; Raine Garrido; Felix Cardoso; Mario Landys; Roselyn Martinez; Humberto Gonzalez; Tamara Hernandez; Rolando Ochoa-Azze; Jose L Perez; Juliet Enriquez; Nibaldo Gonzalez; Yenicet Infante; Luis A Espinosa; Yassel Ramos; Luis Javier González; Carmen Valenzuela; Ana Victoria Casadesus; Briandy Fernandez; Gertrudis Rojas; Beatriz Pérez-Massón; Yaima Tundidor; Ernesto Bermudez; Claudia A Plasencia; Tammy Boggiano; Eduardo Ojito; Fabrizio Chiodo; Sonsire Fernandez; Françoise Paquet; Cheng Fang; Guang-Wu Chen; Daniel G Rivera; Yury Valdes-Balbin; Dagmar Garcia-Rivera; Vicente Verez Bencomo
Journal:  RSC Chem Biol       Date:  2021-12-08

Review 8.  Adjuvants are Key Factors for the Development of Future Vaccines: Lessons from the Finlay Adjuvant Platform.

Authors:  Oliver Pérez; Belkis Romeu; Osmir Cabrera; Elizabeth González; Alexander Batista-Duharte; Alexis Labrada; Rocmira Pérez; Laura M Reyes; Wendy Ramírez; Sergio Sifontes; Nelson Fernández; Miriam Lastre
Journal:  Front Immunol       Date:  2013-12-02       Impact factor: 7.561

9.  Evaluating the immunogenicity of an intranasal vaccine against nicotine in mice using the Adjuvant Finlay Proteoliposome (AFPL1).

Authors:  Nya L Fraleigh; Justin Boudreau; Nitin Bhardwaj; Nelson F Eng; Yanal Murad; Robert Lafrenie; Reinaldo Acevedo; Reynaldo Oliva; Francisco Diaz-Mitoma; Hoang-Thanh Le
Journal:  Heliyon       Date:  2016-08-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.